Invention Grant
- Patent Title: PKLR inhibition in the treatment of NAFLD and HCC
-
Application No.: US16638927Application Date: 2018-08-14
-
Publication No.: US11034960B2Publication Date: 2021-06-15
- Inventor: Adil Mardinoglu , Jan Borén , Mathias Uhién
- Applicant: ScandiEdge Therapeutics AB
- Applicant Address: SE Johanneshov
- Assignee: ScandiEdge Therapeutics AB
- Current Assignee: ScandiEdge Therapeutics AB
- Current Assignee Address: SE Johanneshov
- Agency: Myers Bigel, P.A.
- Priority: EP17186181 20170814
- International Application: PCT/EP2018/072036 WO 20180814
- International Announcement: WO2019/034657 WO 20190221
- Main IPC: A61K48/00
- IPC: A61K48/00 ; C12N15/11 ; C07H21/02 ; C07H21/04 ; C12N15/113
Abstract:
There is provided a medical agent for use in a method of treatment of nonalcoholic fatty liver disease (NAFLD) or hepatocellular carcinoma (HCC), wherein the medical agent comprises a polynucleotide and is capable of silencing or knocking out the PKLR gene.
Public/Granted literature
- US1723024A Exercising or molding tool for facial treatments Public/Granted day:1929-08-06
Information query
